Global Checkpoint Inhibitors Market (2021 to 2030) - Featuring AstraZeneca, Roche Holding and Pfizer Among Others

Dublin, Dec. 07, 2021 (GLOBE NEWSWIRE) -- The "Checkpoint Inhibitors Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

This report provides strategists, marketers and senior management with the critical information they need to assess the global checkpoint inhibitors market.

This report focuses on the checkpoint inhibitors market which is experiencing strong growth. The report gives a guide to the checkpoint inhibitors market which will be shaping and changing our lives over the next ten years and beyond, including the market's response to the challenge of the global pandemic.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.

• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.

• Create regional and country strategies on the basis of local data and analysis.

• Identify growth segments for investment.

• Outperform competitors using forecast data and the drivers and trends shaping the market.

• Understand customers based on the latest market research findings.

• Benchmark performance against key competitors.

• Utilize the relationships between key data sets for superior strategizing.

• Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Where is the largest and fastest growing market for checkpoint inhibitors? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Checkpoint Inhibitors market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider checkpoint inhibitors market, and compares it with other markets.

• The market characteristics section of the report defines and explains the market.

• The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.

• Market segmentations break down market into sub markets.

• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.

• Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

• The checkpoint inhibitors market section of the report gives context. It compares the checkpoint inhibitors market with other segments of the checkpoint inhibitors market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, checkpoint inhibitors indicators comparison.

Major players in the checkpoint inhibitors market are, AstraZeneca PLC, Bristol-Myers Squibb Company, Merck & Co., Inc., Roche Holding AG, Pfizer, Incyte Corporation, Novartis AG, and NewLink Genetics Corporation.

The global checkpoint inhibitors market is expected to grow from $15.29 billion in 2020 to $18.04 billion in 2021 at a compound annual growth rate (CAGR) of 18%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $39.81 billion in 2025 at a CAGR of 22%.

The checkpoint inhibitors market consists of sales of the immune checkpoint inhibitor drugs and related services by entities (organizations, sole traders and partnerships) that produce checkpoint inhibitors for treating cancer. A checkpoint inhibitor is a drug that blocks proteins that stop the body's immune system from killing the cancer cells. One type of cell in the immune system that fights the cancer cells are T-cells. T cells have proteins on them that turn on immune response and other proteins that turn it off. These are called checkpoints. Some checkpoints help T-cells to become active while others help T-cells to switch off. When cancer cells produce high levels of proteins, the switch off checkpoints restrict the immune responses from being strong and sometimes even stops the T-cells from killing the cancer cells. When the checkpoints are blocked by the checkpoint inhibitor from binding with its partner proteins, this allows the T-cells to kill the cancer cells.

The checkpoint inhibitors market covered in this report is segmented by drug into PD-1 inhibitors, PD-L1 inhibitors, CTLA-4, chimeric antigen receptor T-cell, others, and by application into lung cancer, renal cancer, blood cancer, bladder cancer, melanoma, others.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The high cost of checkpoint inhibitor cancer treatment is expected to limit the checkpoint inhibitor market. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, the lack of cost-effective therapies for cancer has influenced the health conditions of the population and has led to a low-average life expectancy. For instance, the cost for a course of intravenous checkpoint inhibitor therapy is around $150,000 to $250,000, which is very expensive, especially for countries without public insurance. Therefore, the high cost of checkpoint inhibitor cancer treatment is expected to limit the checkpoint inhibitor market.

In June 2020, Targovax, a Norway-based biotechnology company, entered into a collaboration with the Explorations in Global Health (ExGloH) division of Leidos for evaluating the potential of using ONCOS, a Targovax's clinical program of oncolytic adenoviruses, as a vector to encode MicrotideT checkpoint inhibitor peptides. Explorations in Global Health (ExGloH) division of Leidos has created a specific, proprietary portfolio of microbially-derived peptides called MicrotideTM that act as immune checkpoint inhibitors. Leidos is a US-based company that deals with defense, aviation, information technology, and biomedical research.

The rise in the number of cancer cases across the globe is likely to contribute to the growth of the checkpoint inhibitors market during the forecast period. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. The four most common types of cancers worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all the new cancer cases. Checkpoint inhibitors targeting the checkpoints are very helpful as cancer therapies. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the checkpoint inhibitors market.

Major companies in the checkpoint inhibitor market are forming partnerships or collaborations for the development of advanced technologies such as bifunctional fusion protein or Y-trap. Most of the patients with cancer do not respond to immune checkpoint inhibitors. To make immunotherapies more effective, a group of researchers has developed the bifunctional fusion protein or Y-trap. This drug is created by fusing a receptor for a protein called TGF-beta that targets checkpoint protein such as PD-L1 or CTLA-4. Y- Trap targets both a checkpoint inhibitor and TGF-beta and gives a more effective way to block the immune suppression and destroys the cancer cells. Merck, a prominent science and technology group, and GSK, a research-based global healthcare company, have announced that they have entered into a global strategic partnership to jointly create and market M7824 (bintrafusp alfa). M7824 is an investigational bi-functional fusion protein immunotherapy that is currently in clinical research, including possible registration trials, for various difficult-to-treat cancers. This includes a Phase II study to investigate M7824 compared to pembrolizumab as a first-line treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC). In another instance, in June 2020, Targovax, a Norway-based biotechnology company that develops immune activators for targeting solid tumors, entered into a collaboration with Leidos' Explorations in Global Health (ExGloH) division for evaluating the potential of using ONCOS, a Targovax's clinical program of oncolytic adenoviruses, as a vector to encode MicrotideT checkpoint inhibitor peptides.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.


Key Topics Covered:

1. Executive Summary

2. Checkpoint Inhibitors Market Characteristics

3. Checkpoint Inhibitors Market Trends and Strategies

4. Impact Of COVID-19 On Checkpoint Inhibitors

5. Checkpoint Inhibitors Market Size and Growth
5.1. Global Checkpoint Inhibitors Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of the Market
5.1.2. Restraints On the Market
5.2. Global Checkpoint Inhibitors Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of the Market
5.2.2. Restraints On the Market

6. Checkpoint Inhibitors Market Segmentation
6.1. Global Checkpoint Inhibitors Market, Segmentation by Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

• PD-1 Inhibitors

• PD-L1 Inhibitors

• CTLA-4

• Chimeric Antigen Receptor T-cell

• Others

6.2. Global Checkpoint Inhibitors Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

• Lung Cancer

• Renal Cancer

• Blood Cancer

• Bladder Cancer

• Melanoma

• Others

6.3. Global Checkpoint Inhibitors Market, Segmentation by End-Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

• Hospitals Pharmacies

• Retail Pharmacies

• Online Pharmacies

7. Checkpoint Inhibitors Market Regional and Country Analysis
7.1. Global Checkpoint Inhibitors Market, Split by Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Checkpoint Inhibitors Market, Split by Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

For more information about this report visit https://www.researchandmarkets.com/r/pkxf3x

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900